Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCTP | Q9UKL6 | 11/20 | 1.00 |
| ▸ | STARD10 | Q9Y365 | 3/20 | 0.72 |
| ▸ | STARD7 | Q9NQZ5 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17066490 | 0.88 | PCTP (0.79) | PCTPSTARD10STARD7ALDH1A1SMN1; SMN2 | |
| SCHEMBL1234489 | 0.88 | PCTP (1.00) | PCTPSTARD10STARD7ALDH1A1SMN1; SMN2 | |
| SCHEMBL1234605 | 0.86 | PCTP (0.79) | PCTPSTARD10STARD7ALDH1A1SMN1; SMN2 | |
| SCHEMBL1235198 | 0.84 | PCTP (1.00) | PCTPSTARD10STARD7ALDH1A1SMN1; SMN2 | |
| SCHEMBL1233503 | 0.84 | PCTP (1.00) | PCTPSTARD10STARD7ALDH1A1SMN1; SMN2 | |
| SCHEMBL1235185 | 0.80 | PCTP (1.00) | PCTPSTARD10STARD7ALDH1A1SMN1; SMN2 | |
| SCHEMBL1234494 | 0.79 | PCTP (0.78) | PCTPSTARD10STARD7ALDH1A1SMN1; SMN2 | |
| SCHEMBL1233505 | 0.75 | PCTP (1.00) | PCTPSTARD10STARD7ALDH1A1SMN1; SMN2 | |
| SCHEMBL16358861 | 0.74 | PCTP (0.61) | PCTPSTARD10STARD7ALDH1A1SMN1; SMN2 | |
| SCHEMBL17066577 | 0.73 | PCTP (0.80) | PCTPSTARD10STARD7KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150336902-A1 | Phosphatidylcholine Transfer Protein Inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2015-11-26 | — | — | US | claimed |
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-10-18 | — | — | US | claimed |
| EP-2467362-A2 | PHOSPHATIDYLCHOLINE TRANSFER PROTEIN INHIBITORS | The Brigham and Women's Hospital, Inc. (US) | 2012-06-27 | — | — | EP | claimed |
| WO-2011022393-A2 | PHOSPHATIDYLCHOLINE TRANSFER PROTEIN INHIBITORS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-02-24 | — | — | WO | claimed |
| US-9556129-B2 | Phosphatidylcholine transfer protein inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556129-B2 | Phosphatidylcholine transfer protein inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150336902-A1 | Phosphatidylcholine Transfer Protein Inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2015-11-26 | — | — | US | disclosed |
| US-9126938-B2 | Phosphatidylcholine transfer protein inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | PCTP, LCAT, CETP | PCTP 1/4885STARD10 1028/4885STARD7 117/4885 |
| US-20150336902-A1 | Phosphatidylcholine Transfer Protein Inhibitors | PCTP, LCAT, CETP | PCTP 1/4885STARD10 1028/4885STARD7 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.